NEW YORK (GenomeWeb) – Agilent Technologies said this week that its PD-L1 IHC 22C3 pharmDx assay has been labeled for an updated use in urothelial carcinoma in Europe. Doctors there can now use the assay to identify urothelial carcinoma patients who are ineligible for cisplatin but may respond to the Merck immunotherapy Keytruda as a first-line treatment option.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.